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ABSTRACT 
Background: Green tea (Camellia sinensis) is a beverage consumed for thousands of 
years. Numerous claims about the benefits of its consumption were stated and 
investigated. As green tea is experiencing a surge in popularity in Western culture and 
as millions of people all over the world drink it every day, it is relevant to understand its 
effects on the human brain. 
Purpose: To assess the current state of knowledge in the literature regarding the effects 
of green tea or green tea extracts, L-theanine and epigallocatechin gallate both 
components of green tea - on general neuropsychology, on the sub-category cognition 
and on brain functions in humans. 
Methods: We systematically searched on PubMed database and selected studies by 
predefined eligibility criteria. We then assessed their quality and extracted data. We 
structured our effort according to the PRISMA statement. 
Outcome: We reviewed and assessed 21 studies, 4 of which were randomised 
controlled trials, 12 cross-over studies (both assessed with an adapted version of the 
DELPHI-list), 4 were cross-sectional studies and one was a cohort study (both assessed 
with an adapted version of the Newcastle-Ottawa assessment scale). The average study 
quality as appraised by means of the DELPHI-list was good (8.06/9); the studies 
evaluated with the Newcastle-Ottawa-scale were also good (6.7/9). 
Conclusions:  The reviewed studies presented evidence that green tea influences 
psychopathological symptoms (e.g. reduction of anxiety), cognition (e.g. benefits in 
memory and attention) and brain function (e.g. activation of working memory seen in 
functional MRI). The effects of green tea cannot be attributed to a single constituent of 
the beverage. This is exemplified in the finding that beneficial green tea effects on 
cognition are observed under the combined influence of both caffeine and L-theanine, 
whereas separate administration of either substance was found to have a lesser impact.  
 
Keywords: Green tea, Cognitive functioning, Brain functions 
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Abbreviations: 
AMPA - Aminomethylphosphonic acid, DELPHI -  Structured communication 
technique that relies on a panel of experts, DLPFC - Dorsolateral prefrontal 
cortex, Dyrk1A - Dual specificity tyrosine-(Y)-phosphorylation-regulated kinase 
1A, EEG – Electroencephalography, EGCG - Epigallocatechin gallate, fMRI - 
Functional magnetic resonance imaging, GABAA - γ-aminobutyric acid receptor A, 
GTE - Green tea extract, HIV - human immunodeficiency virus, LORETA - low 
resolution brain electromagnetic tomography, MMSE - Mini mental state 
examination, NIRS - Near-infrared spectroscopy, NMDA - N-Methyl-D-aspartate, 
PANSS - Positive and negative syndrome scale, PICOS - Patient-intervention-
control-outcome-study design, PPI - Prepulse inhibition, PRISMA - referred 
reporting items for systematic reviews and meta-analyses, UPD - Uridine 
diphosphate
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Introduction 
 
Camellia sinensis, commonly known as green tea, has a long history in human culture 
and it has been considered to have medical properties for many years. There has 
recently been a great surge of interest in the health benefits of green tea; this is at least 
in part due to the effect of increasing consumption of green tea in Western countries. A 
trial in rats claims that polyphenols that are specific to green tea might provide 
functional neuroprotection in Parkinson„s disease (Guo et al., 2007). Yet scientific 
interest in the medical qualities of green tea goes beyond neurodegenerative diseases, as 
reported in animal studies, showing that green tea polyphenols inhibited the growth of 
bladder tumour cells (Chen et al., 2004). Moreover, there is evidence that green tea acts 
as an antiviral agent in HIV-infection, although it is still unclear how these findings 
should be applied to current therapy (Nance and Shearer, 2003). Pastore et al. have 
reviewed the broad spectrum of known or suspected effects of green tea (Pastore and 
Fratellone, 2006).  
 
Green tea is prepared from steamed leaves of Camellia sinensis in absence of 
fermentation (Chow and Hakim, 2011)
 
and is composed of many substances: most 
importantly catechins (30 - 42% of solid extract weight), of which epigallocatechin 
gallate (EGCG) is the most abundant (65%)(Nagle et al., 2006) (Scholey et al., 2012), 
followed by theanine (4 - 6%) and caffeine (3 - 4%)(Chow and Hakim, 2011). Black tea 
contains considerably lower amounts of non-oxidised catechins as it is produced by 
allowing enzymatic oxidation to occur in harvested leaves of Camellia sinensis, 
resulting in fewer catechins (3 - 10%) due to the formation of thearubigins and 
theaflavins (12 - 18% and 3 - 6% respectively) (Chow and Hakim, 2011). It is 
noteworthy that the addition of milk - as is customary in black tea - can decrease both 
the antioxidant qualities of polyphenols (Bourassa et al, 2013) and - in elevated 
quantities (more than 50 ml in a 200 ml cup) - the concentration of L-theanine (Keenan 
et al., 2011).  
The focus of the present review is on the effects of Epigallocatechin gallate (EGCG) 
and theanine, as Camellia sinensis is the main dietary source of both EGCG (Borgwardt 
et al., 2012)
 
and L-theanine (Scheid et al., 2012). In fact, EGCG possesses anti-
inflammatory and antioxidant qualities (Scapagnini et al., 2011). Several animal studies 
suggested that EGCG can pass the blood-brain barrier (Lin et al., 2007; Suganuma et 
al., 1998), whereas Zini et al. could not trace detectable amounts of EGCG in the 
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cerebrospinal fluid of multiple sclerosis patients after consumption of green tea (Zini et 
al., 2006). More recently, an in vitro study by Faria et al. (Faria et al., 2011) showed 
that the human brain capillary endothelial cells forming the blood-brain barrier (BBB) 
permit the passage of catechins and epicatechins. The bioavailability of EGCG and 
other green tea catechins appears to be less marginal than previously proposed if the 
calculation includes metabolites derived from colonic microflora: the calculated 
bioavailability then increases from 4% (just EGCG) to 39% (EGCG including 
metabolites) (Del Rio et al., 2010). The same study found that a peak plasma 
concentration 0.08 µmol/l of EGCG was observed at 1.4h after oral administration of 
11.8 mg EGCG to humans. 
On the other hand, L-Theanine reached in human volunteers a peak plasma 
concentration of 26.5 µmol/l at 0.8 hours after oral intake of 250 ml of green tea (Scheid 
et al., 2012). L-Theanine passes through the BBB, interacts with the glutamine 
transporter and inhibits neural incorporation of glutamine (Kakuda, 2011). 
 
Although several implications of the neuro-modulating properties of green tea have 
already been investigated, no previous studies reviewed green tea's impact on the 
human brain. Thus, the aim of this systematic review was to assess the effects of green 
tea on cognition and human brain functions. 
 
 
 
Material and methods 
 
Eligibility Criteria 
We defined five eligibility criteria for our search results: (1) The search result was a 
study or a clinical trial. (2) The search result had an in vivo design. (3) The search result 
was a study conducted on humans. (4) The search result featured an intervention with 
and without exposure to either green tea (extract), EGCG, L-theanine or combinations 
thereof. (5) The search result contained outcomes pertaining to the fields of brain 
functions, neurology or neuropsychology. Criteria (1-3) were set in place to assure that 
an eligible search result would provide data that could easily be translated to clinical or 
nutritional questions. Criterion (4) was devised to assure that search results contained 
the desired green tea components. Finally, criterion (5) guaranteed that the outcome was 
in the predefined fields of interest. 
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Keywords 
We selected seven key words to best cover and represent the different components of 
our initial question: green tea, epigallocatechin gallate, L-theanine, cognition, cognitive 
functioning, brain functions, psychology. The first three key words covered the desired 
intervention or exposure; the other four key words related to the desired outcome. 
“Green tea effect” was simplified for this purpose and assumed to be the effect of green 
tea or of its two main defining components. 
 
Information source 
We chose the online database PubMed as sole information source. We limited ourselves 
to English language results and considered results regardless of year or publication 
status. The search was conducted from March 25
th
 2013 to January 19
th
 2015. 
 
Search strategy 
We systematically searched our information source for our key words. We used all the 
permutations of intervention-keywords with outcome-keywords. The hits under 
“cognitive functioning” were added to those for “cognition” in Fig.1 for the sake of 
simplicity. We then screened the results for duplicates and eligibility criteria. The 
extract of this process was included in our review. 
 
 
Data extraction and quality assessment 
This systematic review was structured according to the PRISMA checklist 5. One 
reviewer (E.M.) extracted the data. 
Firstly, we focused on five categories at the level of the study:  
• Participant characteristics, number, gender, mean age and - if  present - other 
specific defining factors.  
• Intervention characteristics, which means substances that we had previously 
searched for and substances that were inextricably linked to them by the study 
design - e.g. caffeine -, both with dosages.  
• Control characteristics, which documented the presence or absence of controls - 
most notably placebo.  
• Study Design that was explicitly stated in the respective study.  
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• Finally, only outcome measures were listed that could possibly produce an 
outcome pre-specified in eligibility criterion (5). If there were significant data, 
these were highlighted. 
When extracting data from the observational studies, we substituted the term 
“Intervention” for the more accurate term “Exposure” as the substances in question 
were no longer administered under standard conditions, yet consumed habitually. We 
also replaced the category “Control” with the factor “Time” to indicate when a result 
was reported and the period of time for which it was monitored if there was a follow-up. 
The other data extraction categories remained the same. 
 
Secondly, we extracted the outcome. We focussed on four aspects of the outcome of 
each study:  
• Cardiovascular effects,  
• Neuropsychological effects,  
• Neurocognitive effects 
• Brain functions.  
These data extraction groups were the same for all studies regardless of their design. 
 
Thirdly, we conducted quality assessments of the 21 studies to systematically assess 
their most important biases and weaknesses. We chose the DELPHI list (Verhagen et 
al., 1998) to rate the experimental trials and the Newcastle - Ottawa scale (De la Torre 
et al., 2014) to evaluate the quality of the observational studies. However, the tools had 
to be adapted for certain study designs: as the DELPHI list was specifically designed for 
randomised controlled trials, some adjustments (de Morton, 2009) had to be made to 
assess the quality of repeated measures designs.  
A similar difficulty arose with the Newcastle - Ottawa scale, which was originally 
conceived to rate cohort studies and case-control studies; therefore, we had to make 
some adaptations for cross-sectional studies. The Appendix contains full details of the 
quality assessment tools and full assessment. 
 
Types of investigations 
The trials with a crossover design - also known as ‚within subject„ or ‚repeated 
measures„ design - examined the various effects of green tea extract, EGCG or L-
theanine on healthy subjects. For this purpose the test subjects underwent both placebo 
and ‚treatment„ conditions over the entire course of the trial. Between the testing dates a 
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wash-out period was observed, for the participants to return to baseline values. The 
(first) testing was performed within 90 minutes after intake. To correct for order effects 
(counter-)balancing according to a Latin Square design was applied. The methods used 
in the scrutinised body of work are summarized in Table 1. 
 
Results 
 
Study selection 
We identified 165 publications - 117 after eliminating 48 duplicates - and proceeded to 
screen these results for eligibility using the inclusion criteria: (1) We selected only 
studies or trials (26 reviews/ essays/ book chapters were excluded); (2) The subjects had 
to be human (51 animal studies were excluded); (3) The study had to be in vivo; there 
were no in vitro studies; (4) Either green tea (green tea extract), EGCG, L-theanine or 
combinations of these were consumed (five studies were excluded; mainly because 
other compounds not naturally present in green tea were inextricably linked to the 
outcome); (5) There had to be an outcome related to brain functions, neurology or 
neuropsychology (fourteen results were excluded, as they produced a variety of 
different outcomes). This screening finally gave 21 results (Fig. 1). If only parts of a 
search result met all eligibility criteria, the parts that met the criteria were extracted and 
included - provided all five criteria were fulfilled. 
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FIGURE 1 Flowchart of the selection procedure 
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Types of study design 
Sixteen (16) of these 21 results were experimental trials and five were observational 
studies (Table 2). The experimental trials included four randomised controlled trials and 
twelve with repeated measures. The former investigating sub-acute or chronic effects of 
green tea or components thereof, the latter measuring acute green tea effects or acute 
effects of green tea components. The observational studies included one cohort study 
and four cross-sectional studies and measured for long-term green tea effects (Table 2). 
 
Green tea and Green tea extract (GTE) 
Three experimental studies (Borgwardt et al., 2012; Park et al., 2011; Schmidt et al., 
2014) investigated the effects of green tea or green tea extract: two the acute effects in 
healthy participants, one the chronic effects in patients with mild cognitive impairment 
(Park et al., 2011).  
The neuroimaging study by Schmidt et al. (Schmidt et al., 2014) employed functional 
magnetic resonance imaging (fMRI) to demonstrate that green tea acted on working 
memory by increasing connectivity from the right parietal lobule to the middle frontal 
gyrus and thus improved cognitive task performance in this way. Another neuro-
imaging study by Borgwardt et al. (Borgwardt et al., 2012) was the first study to analyse 
green tea effects by means of fMRI and found that green tea significantly increased 
activation in the dorsolateral prefrontal cortex (DLPFC); the authors had suggested in 
advance that this was an “a priori region of interest”, as it is important in processing 
working memory. The performance in the working memory task was not recorded. 
Thus, no cognitive benefit was demonstrated, as this study only measured brain 
activation. Park et al. (Park et al., 2011) showed that combined administration of GTE 
and L-theanine was beneficial to a more affected subgroup (Mini Mental State 
Examination (MMSE) 21-23) of their sample of participants suffering from mild 
cognitive impairment (MMSE 21-26), in that it increased verbal and visuospatial 
memory and attention. Twenty-three (23) random EEGs, equally divided between 
intervention and control, showed that this treatment significantly enhanced theta waves 
during the states “eyes open” and “reading” (but not in “eyes closed”). 
All of the five (Feng et al., 2010; Hozawa et al., 2009; Kuriyama et al., 2006; Shimbo et 
al., 2005; Tomata et al., 2012) observational studies investigated the long-term effects 
of exposure to green tea consumption. Tomata et al. (Tomata et al., 2012) showed that 
consumption of green tea reduced the risk of functional disability in a population of 
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over sixty-five year olds; this was directly linked to the quantity habitually consumed. 
Feng et al. (Feng et al., 2010) demonstrated that exposure enhanced performance in the 
MMSE, as well as the scores for memory, executive function and speed of information 
processing speed, all tested as part of a wide-range cognitive test battery in over 55-year 
olds. Hozawa et al. (Hozawa et al., 2009) showed that green tea consumption reduced 
the odds ratio for physiological distress in a dose-dependent manner in a group of over 
40-year olds. Kuriyama et al. (Kuriyama et al., 2006) substantiated considered that 
green tea consumption decreased the hazard ratio for cognitive impairment, which was 
defined as an MMSE score under 26. 
Shimbo et al. (Shimbo et al., 2005) studied a community based sample of 20- to 69-year 
olds, with a mean age of 46. They concluded that green tea had no significant 
neuropsychological or cognitive effects.  
 
Epigallocatechin gallate (EGCG) 
Four experimental studies (Brown et al., 2009; De la Torre et al., 2014; Scholey et al., 
2012; Wightman et al., 2012)
 
analysed the effects of EGCG. Two of these used did so 
analysing acute effects in healthy volunteers. One study was restricted to obese patients 
(Brown et al., 2009) and one to patients with Down's syndrome (De la Torre et al., 
2014) and examined long-term effects. 
Scholey et al. (Scholey et al., 2012) reported that EGCG-intake had a significant 
calming effect and relieved stress and increased the overall activity of alpha-, beta- and 
theta-waves in the EEG. A low resolution brain electromagnetic tomogram (LORETA) 
showed that the frontal and medial frontal gyrus were the source of this activation. With 
near infrared spectroscopy (NIRS), Wightman et al. (Wightman et al., 2012) showed 
that the administration of EGCG reduced cerebral blood flow in the frontal cortex. De la 
Torre et al. (De la Torre et al., 2014) investigated the effects of EGCG in patients with 
Down's syndrome and found that treatment significantly improved visual memory 
recognition after one month,  and social functioning and increased plasma homocysteine 
levels (hcy). It was shown with transgenic mice that hcy is a valid biomarker for 
hippocampal dual specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A 
(Dyrk1A) activity. Therefore, the increased hcy levels were interpreted as EGCG-
mediated inactivation of Dyrk1A - a kinase which when over-expressed may be 
responsible for some of the neurocognitive deficits in Down's syndrome. Brown et al. 
(Brown et al., 2009) demonstrated the ability of EGCG to reduce diastolic blood 
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pressure and to improve the hedonic tone. These results were a secondary outcome of an 
investigation of potential insulin-modifying properties of EGCG in obese patients. 
 
L-Theanine 
Ten experimental studies (Einother et al., 2010; Giesbrecht et al., 2010; Haskell et al., 
2008; Kelly et al., 2008; Kimura et al., 2007; Ota et al., 2014; Owen et al., 2008; Park et 
al., 2011; Ritsner et al., 2011; Yoto et al., 2012) focussed on the effects of L-theanine 
intake. Nine (Einöther et al., 2010; Giesbrecht et al., 2010; Haskell et al., 2008; Kelly et 
al., 2008; Kimura et al., 2007; Ota et al., 2014; Owen et al., 2008; Park et al., 2011; 
Yoto et al., 2012) of these employed within-subject designs and healthy participants for 
acute effects, whereas one randomised controlled trial investigated these long-term 
effects in a population of patients with the diagnosis of schizophrenia or a 
schizoaffective disorder (Ritsner et al., 2011)
,
. Three studies (Kimura et al., 2007; Ota et 
al., 2014; Ritsner et al., 2011) investigated the isolated effects of L-theanine; one 
explored the effect of L-theanine combined with GTE (Park et al., 2011) (and was 
already summarised in the previous chapter), while the other six (Einother et al., 2010; 
Giesbrecht et al., 2010; Haskell et al., 2008; Kelly et al., 2008; Owen et al., 2008; Yoto 
et al., 2012) included caffeine, as L-theanine naturally occurs together with caffeine. Of 
these studies, only the outcomes for L-theanine alone or for L-theanine and caffeine 
together were extracted (and identified accordingly) - the outcome caused by caffeine 
alone was not extracted. 
Ota et al. (Ota et al., 2014) demonstrated that L-theanine increased prepulse inhibition 
(PPI) and thus sensorimotor gating. The increase in PPI was not correlated with the 
dose of L-theanine. Yoto et al.(Yoto et al., 2012) discovered that L-theanine reduced the 
elevation of systolic blood pressure caused by a stressor-task in a subgroup they defined 
as “high stress-responders”; these were participants whose blood pressure was elevated 
by at least 9 mmHg during the stress task under placebo treatment. Moreover, this 
intervention reduced tension and anxiety (by decreasing tension-anxiety scores in the 
profile of mood states). Giesbrecht et al. (Giesbrecht et al., 2010) reported that 
combined treatment of L-theanine and caffeine not only raised systolic blood pressure, 
but also made the volunteers feel more alert and less tired. Moreover, it enhanced 
attention (measured by an attention-switching task). On the other hand, Einöther et al. 
(Einöther et al., 2010) - using a very similar study setup - merely produced evidence for 
the attention-improving properties of combined treatment using an attention switching 
task. However, there was no increase in self-reported alertness, contrasting Giesbrecht„s 
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et al. (Giesbrecht et al., 2010)
 
findings. Owen et al. (Owen et al., 2008) also showed that 
a combination of L-theanine and caffeine led to a shorter response time and greater 
accuracy in an attention-switching task. Kelly et al. (Kelly et al., 2008) found that L-
theanine only had a beneficial effect on accuracy and hit rate in a “behavioural test” 
(relative to a placebo condition and a no-intervention condition) when combined with 
caffeine, but not on its own. The same was true of the diminution of the overall tonic 
alpha amplitude in EEG. Haskell et al. (Haskell et al., 2008) reported that intake of L-
theanine alone led to headache and worsened the performance in a test with seven serial 
subtractions, whereas the combination of L-theanine and caffeine made the participants 
feel more alert, less tired and less afflicted with mental fatigue and headache, as shown 
by a visual analogue scale. In addition, this treatment was favourable for simple reaction 
time, the reaction time in testing numerical working memory, accuracy in rapid visual 
information processing, and accuracy of sentence verification, as well as improving 
scores in delayed word recognition time. Kimura et al. (Kimura et al., 2007) found that 
L-theanine reduced stress-induced heart rate and increases in secretory immunoglobulin 
A. They also reported a reduction in perceived stress and anxiety, using visual analogue 
scales and a state-trait anxiety inventory.  
Ritsner et al. (Ritsner et al., 2011) proved demonstrated that augmentation of 
antipsychotic medication with L-theanine was beneficial to his group of patients 
suffering from schizophrenia or schizoaffective disorder. The positive and negative 
syndrome scale (PANSS) revealed a reduction in positive and general psychopathology 
in its three dimension model. The amelioration of negative syndromes was not 
significant after Bonferroni correction. PANSS also revealed a reduction in activation 
factor and positive factor in its five-dimensional model. Moreover, Ritsner et al. 
(Ritsner et al., 2011)
 
found that the treatment lowered anxiety according to the Hamilton 
anxiety rating scale.  
 
Acute cognitive effects 
Five experimental cross-over studies (Giesbrecht et al., 2010; Einöther et al., 2010; 
Owen et al., 2008; Kelly et al., 2008; Haskell et al., 2008) on healthy participants 
focussed on the acute cognitive effects of L-theanine combined with caffeine. 
Giesbrecht et al. (Giesbrecht et al., 2010) reported that combined treatment of L-
theanine and caffeine not only raised systolic blood pressure, but also enhanced 
attention (measured by an attention-switching task). Einöther et al. (Einöther et al., 
2010)  produced evidence for the attention-improving properties of combined treatment 
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using an attention switching task. Owen et al. (Owen et al., 2008) also showed that a 
combination of L-theanine and caffeine led to a shorter response time and greater 
accuracy in an attention-switching task. Kelly et al. (Kelly et al., 2008) found that L-
theanine only had a beneficial effect on accuracy and hit rate in a “behavioural test” 
(relative to a placebo condition and a no-intervention condition) when combined with 
caffeine, but not on its own. Haskell et al. (Haskell et al., 2008) reported that intake of 
L-theanine alone led to headache and worsened the performance in a test with seven 
serial subtractions, whereas the combination of L-theanine and caffeine was favourable 
for simple reaction time, the reaction time in testing numerical working memory, 
accuracy in rapid visual information processing, and accuracy of sentence verification, 
as well as improving scores in delayed word recognition time.  
 
Acute mood effects 
Five experimental cross-over studies (Scholey et al., 2012 Yoto et al., 2012; Kimura et 
al., 2007 Giesbrecht et al., 2010; Haskell et al., 2008) with healthy participants 
investigated acute effects on mood: one of EGCG (Scholey et al., 2012), two of L-
theanine(Yoto et al., 2012; Kimura et al., 2007) and two of L-theanine combined with 
caffeine (Giesbrecht et al., 2010; Haskell et al., 2008). 
Scholey et al. (Scholey et al., 2012) reported that EGCG-intake had a significant 
calming effect and relieved stress as shown by visual analogue scales. Yoto et al.(Yoto 
et al., 2012) discovered that L-theanine reduced the elevation of systolic blood pressure 
caused by a stressor-task in a subgroup they defined as “high stress-responders”; these 
were participants whose blood pressure was elevated by at least 9 mmHg during the 
stress task under placebo treatment. Moreover, this intervention reduced tension and 
anxiety (by decreasing tension-anxiety scores in the profile of mood states). Kimura et 
al. (Kimura et al., 2007) found that L-theanine reduced stress-induced heart rate and 
increases in secretory immunoglobulin A. They also reported a reduction in perceived 
stress and anxiety, using visual analogue scales and a state-trait anxiety inventory. 
Giesbrecht et al. (Giesbrecht et al., 2010) reported that combined treatment of L-
theanine and caffeine made the volunteers feel more alert and less tired. On the other 
hand, Einöther et al. (Einöther et al., 2010) - using a very similar study setup - found no 
increase in self-reported alertness, contrasting Giesbrecht„s et al. (Giesbrecht et al., 
2010)
 
findings. Haskell et al. (Haskell et al., 2008) reported that intake of the 
combination of L-theanine and caffeine made the participants feel more alert, less tired 
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and less afflicted with mental fatigue and headache, as shown by a visual analogue 
scale.  
 
Chronic effects (associated with habitual consumption) 
Four randomised controlled trials (Park et al., 2011; De la Torre et al., 2014 ; Brown et 
al., 2009; Ritsner et al., 2011) on different kinds of clinical groups investigated non-
acute effects of green tea or green tea components. Two did so on cognitive effects, one 
with GTE combined with L-theanine (Park et al., 2011) and one with EGCG (De la 
Torre et al., 2014). Two more trials focussed on effects on mood, one of EGCG (Brown 
et al., 2009) and one of L-theanine (Ritsner et al., 2011). Furthermore, four 
observational studies investigated long-term cognitive effects (Feng et al., 2010 ; 
Kuriyama et al., 2006 ; Shimbo et al., 2005; Tomata et al., 2012)  and one long-term 
effects on mood (Hozawa et al., 2009) of habitual green tea consumption on samples of 
the general population. 
Park et al. (Park et al., 2011) showed that combined administration of GTE and L-
theanine - twice daily over 16 weeks - was beneficial to a more affected subgroup (Mini 
Mental State Examination (MMSE) 21-23) of their sample of participants suffering 
from mild cognitive impairment (MMSE 21-26), in that it increased verbal and 
visuospatial memory and attention. De la Torre et al. (De la Torre et al., 2014) 
investigated the effects of daily EGCG administration over twelve weeks in patients 
with Down's syndrome and found that treatment significantly improved visual memory 
recognition after one month,  and social functioning and increased plasma homocysteine 
levels (hcy). It was shown with transgenic mice that hcy is a valid biomarker for 
hippocampal dual specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A 
(Dyrk1A) activity. Therefore, the increased hcy levels were interpreted as EGCG-
mediated inactivation of Dyrk1A - a kinase which when over-expressed may be 
responsible for some of the neurocognitive deficits in Down's syndrome. Brown et al. 
(Brown et al., 2009) demonstrated the ability of EGCG to reduce diastolic blood 
pressure and to improve the hedonic tone. These results were a secondary outcome of an 
investigation of potential insulin-modifying properties of EGCG in obese patients over 
eight weeks. Ritsner et al. (Ritsner et al., 2011) proved demonstrated that augmentation 
of antipsychotic medication with L-theanine over eight weeks was beneficial to his 
group of patients suffering from schizophrenia or schizoaffective disorder. The positive 
and negative syndrome scale (PANSS) revealed a reduction in positive and general 
psychopathology in its three dimension model. The amelioration of negative syndromes 
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was not significant after Bonferroni correction. PANSS also revealed a reduction in 
activation factor and positive factor in its five-dimensional model. Moreover, Ritsner et 
al. (Ritsner et al., 2011)
 
found that the treatment lowered anxiety according to the 
Hamilton anxiety rating scale. 
Tomata et al. (Tomata et al., 2012) showed that consumption of green tea reduced the 
risk of functional disability in a population of over sixty-five year olds; this was directly 
linked to the quantity habitually consumed. Feng et al. (Feng et al., 2010) demonstrated 
that exposure enhanced performance in the MMSE, as well as the scores for memory, 
executive function and speed of information processing speed, all tested as part of a 
wide-range cognitive test battery in over 55-year olds. Kuriyama et al. (Kuriyama et al., 
2006) substantiated considered that green tea consumption decreased the hazard ratio 
for cognitive impairment, which was defined as an MMSE score under 26. 
Shimbo et al. (Shimbo et al., 2005) studied a community based sample of 20- to 69-year 
olds, with a mean age of 46. They concluded that green tea had no significant 
neuropsychological or cognitive effects. Hozawa et al. (Hozawa et al., 2009) showed 
that green tea consumption reduced the odds ratio for physiological distress in a dose-
dependent manner in a group of over 40-year olds. 
 
Effects on brain function 
Six experimental cross-over studies (Borgwardt et al., 2012; Schmidt et al., 2014, 
Scholey et al., 2012; Wightman et al., 2012; Ota et al., 2014; Kelly et al., 2008 ) on 
healthy participants produced results on brain function: two with GTE (Borgwardt et al., 
2012; Schmidt et al., 2014 ) two with EGCG (Scholey et al., 2012; Wightman et al., 
2012), one with just L-theanine(Ota et al., 2014) and one with L-theanine combined 
with caffeine (Kelly et al., 2008). Also, one randomised controlled trial (Park et al., 
2011) researching the effects of a combination of GTE and L-theanine contained results 
pertaining to brain functions. 
The neuroimaging study by Schmidt et al. (Schmidt et al., 2014) employed functional 
magnetic resonance imaging (fMRI) to demonstrate that green tea in the form of GTE 
acted on working memory by increasing connectivity from the right parietal lobule to 
the middle frontal gyrus and thus improved cognitive task performance. Another neuro-
imaging study by Borgwardt et al. (Borgwardt et al., 2012) was the first study to analyse 
green tea effects by means of fMRI and found that GTE significantly increased 
activation in the dorsolateral prefrontal cortex (DLPFC); the authors had suggested in 
advance that this was an “a priori region of interest”, as it is important in processing 
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working memory. Scholey et al. (Scholey et al., 2012) reported that EGCG-intake 
increased the overall activity of alpha-, beta- and theta-waves in the EEG. A low 
resolution brain electromagnetic tomogram (LORETA) showed that the frontal and 
medial frontal gyrus were the source of this activation. With near infrared spectroscopy 
(NIRS), Wightman et al. (Wightman et al., 2012) showed that the administration of 
EGCG reduced cerebral blood flow in the frontal cortex. Ota et al. (Ota et al., 2014) 
demonstrated that L-theanine increased prepulse inhibition (PPI) and thus sensorimotor 
gating. The increase in PPI was not correlated with the dose of L-theanine. Kelly et al. 
(Kelly et al., 2008) found that L-theanine only diminished the overall tonic alpha 
amplitude in EEG when combined with caffeine, but not on its own.  
Park et al. (Park et al., 2011) administered a combination of GTE and L-theanine twice 
daily over 16 weeks and performed 23 random EEG on their sample of participants 
suffering from mild cognitive impairment (MMSE 21-26), equally divided between 
intervention and control. The intervention significantly enhanced theta waves during the 
states “eyes open” and “reading” (but not in “eyes closed”). 
 
Quality assessment 
Our assessment of the sixteen experimental studies was in accordance with the Final 
Delphi List (on study level, e.g. risk of bias) and showed that the general quality was 
good (8.25/9). The studies of Scholey et al. (Scholey et al., 2012), Giesbrecht et 
al.(Giesbrecht et al., 2010), Einöther et al. (Einöther et al., 2010), Owen et al. (Owen et 
al., 2008) Haskell et al. (Haskell et al., 2008), Ritsner et al. (Ritsner et al., 2011) and  
Park et al. (Park et al., 2011) were excellent (9/9), whereas the paper of Kelly et al. 
(Kelly et al., 2008) scored the lowest and was still deemed fair (6/9). This assessment 
took place at the study level. 
Our assessment of the five observational studies was performed with the Newcastle-
Ottawa quality assessment scale (on the study and outcome level, e.g. risk of bias) and 
showed that the average quality was good (6.7/9). Tomata„s et al. (Tomata et al., 2012) 
cohort study was at the high end of good (8/9). This assessment took place at the study 
level and at the outcome level (the entire quality assessment can be found in Appendix 
II) . 
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Discussion 
 
This systematic review aimed to establish the current status of knowledge regarding the 
effects of green tea consumption on cognition and human brain function. Green tea and 
its main ingredients, EGCG and L-theanine, can enhance cognition, neuropsychology 
and brain functions, as the majority of the reviewed studies suggest. The research 
findings on habitual, daily green tea consumption of at least 100 ml per day suggest that 
the principle long-term benefits are improved mental facilities, a more relaxed state of 
mind and a lower risk of dementia. Those effects appear to increase dose-dependently 
up to a consumption of 500 ml per day - an even greater consumption of green tea was 
not investigated. No author reported disparate findings. Most of the authors attribute the 
beneficial effects of green tea to the high levels of EGCG and other antioxidants in 
green tea leaves (Higdon and Frei, 2003; Nagle et al., 2006; Scapagnini et al., 2011) and 
iron-chelation (Mandel et al., 2011). L-theanine and vitamin C are both present in the 
beverage and may have secondary long-term beneficial effects. It seems unlikely that 
vitamin is the sole cause of the discovered benefits, as Kuriyama et al. (Kuriyama et al., 
2006) adjusted for non-dietary vitamin C intake and found little change in their results.  
The studies investigating the controlled administration of green tea extract found short-
term benefits in memory and attention as well as an increase in the activation of a brain 
area responsible for mediating working memory, as demonstrated by fMRI. These 
effects may be linked to the antioxidant (Higdon and Frei, 2003; Nagle et al., 2006; 
Scapagnini et al., 2011) and iron-chelating (Davinelli et al., 2012; Levites et al., 2002; 
Mandel et al., 2011) qualities of EGCG present in the extract. EGCG may also protect 
against β-amyloid neurotoxicity, perhaps through the protein kinase C pathway, as 
found in a study in mice (Levites et al., 2003). On the other hand, Schmidt et al. 
(Schmidt et al., 2014) proposed that green tea extract might enhance parieto-frontal 
connectivity by modulating the synaptic plasticity of NMDA-receptors. This effect is 
modulated by working memory and is measurable using fMRI methods.  
Administration of EGCG alone was found to have a calming effect on mood as well as 
an impact on brain functions, as detected by EEG and NIRS. There was an overall 
increase in alpha, beta and theta activity which could be linked to areas in the frontal 
gyrus; this is consistent with the increased activity of the working memory indicated in 
fMRI, since the scrutinised functional structure, which is the dorsolateral prefrontal 
cortex, is mostly located in the anatomical region of the frontal gyrus. However, the 
NIRS results suggest reduced cerebral blood flow in the frontal cortex and a lower 
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concentration of both oxygenated and total haemoglobin after administration of the 
lower of two trial doses of EGCG. The calming EGCG effect may be linked to 
interaction with the GABAA receptor (Adachi et al., 2006). The only documented 
cognitive improvement of EGCG-only therapy was reported in patients with Down's 
Syndrome, where EGCG normalised hippocampal Dyrk1A activity (De la Torre et al., 
2014). Improvements in object recognition were attributed to EGCG effects in the 
hippocampus and perirhinal cortex; benefits in working memory indicate effects in the 
prefrontal cortex. 
Few short-term beneficial effects were reported with L-theanine alone: two studies 
found reductions in stress and tension. A third study (Feng et al., 2010) failed to 
confirm the relaxing qualities of L-theanine, but found that it caused headaches and 
decreased cognitive performance in the task of subtracting serial sevens, the latter being 
consistent with previous findings of detrimental L-theanine effects in an auditory 
attention task (Gomez-Ramirez et al., 2007). In contrast, L-theanine was shown to 
increase prepulse inhibition to auditory stimuli, resulting in fewer startling responses 
and possibly increased focus (Ota et al., 2014). The study that supplemented L-theanine 
to patients diagnosed with schizophrenia and receiving antipsychotic drugs also failed to 
identify cognitive improvements, but also documented a desirable long-term effect on 
mood (Ritsner et al., 2011). Kakuda„s review (Kakuda, 2011) of animal model studies 
on the neuroprotective effects of L-theanine described several mechanisms by which the 
glutamate analogue L-theanine might protect neuronal function. The glutamate 
excitotoxicity of extracellular glutamate may be reduced by antagonistic action on the 
glutamate receptors NMDA, AMPA and kainate, or by acting on the glutamine 
transporter. . 
Beneficial short-term effects were documented for a combination of L-theanine and 
caffeine in every study in which this was tested. These generally differed from the 
effects of L-theanine or caffeine alone, which perhaps indicates that the two substances 
act synergistically, although this has not yet been investigated at the receptor level 
(Haskell et al., 2008). Even tough no acute cognitive effects of L-theanine, but many 
such effects of caffeine are reported in the scrutinised studies, the documented cognitive 
effects of a combination of the two compounds cannot be attributed to caffeine alone: 
Haskell et al. (Haskell et al., 2008) found that memory was unaffected by both caffeine 
or L-theanine, whereas the combined substances significantly improved memory 
measures. Similarly, Kelly et al. (Kelly et al., 2008) recorded no effect of either L-
theanine or caffeine on hit-rate, yet a significant improvement when the to interventions 
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were combined. This L-theanine potentiation of acute cognitive effects of caffeine 
perhaps indicates that the two substances act synergistically, although this has not yet 
been investigated at the receptor level (Haskell et al., 2008). The spectrum of the 
recorded acute effects of L-theanine combined with caffeine is broad - ranging from 
reducing mental tiredness to improving cognitive qualities related to attention and 
memory, to reduced overall tonic alpha amplitude in the EEG. No documented effect of 
the combined substances is detrimental. While the interpretation of the EEG findings 
(Kelly et al., 2008) is difficult to put into context, the effects cannot be regarded as 
detrimental, as cognitive performance was improved in speed and accuracy. It is unclear 
whether L-theanine increases (Nobre et al., 2008) or reduces (Kelly et al., 2008) alpha 
activity in the EEG and how the provoked changes in alpha activity should be 
interpreted; either could be beneficial (Kelly et al., 2008), e.g. through a shift from 
background alpha activity towards attention-related alpha activity during demanding 
tasks (Gomez-Ramirez et al., 2007).  
A review by Bryan focussed on neuropsychological effects and analysed studies on 
caffeine and L-theanine. This concluded that the combined substances have more effect 
on cognitive tasks than on mood (Bryan, 2008). Another review by Camfield et 
al.(Camfield et al., 2014) contains a meta-analysis of L-theanine and caffeine studies 
and concluded that a combination of these two compounds increased both self-reported 
alertness as well as switching task accuracy in the first two hours after consumption. 
 
There is a doubtlessly a certain degree of overlap between green tea effects research and 
caffeine effects research. Even though the latter is not a focus of the systematic review, 
it is interesting to note, that apart from the well documented acute cognitive effects of 
caffeine in healthy humans, there is evidence that is suggestive of long term memory 
consolidation (Borota et al., 2014).  
When comparing green tea (compounds) with nicotine, it is noticeable that nicotine has 
been shown to act on (among other loci) on the DLPFC as seen in fMRI (Ettinger et al, 
2009) - reminiscent of GTE. Ettinger et al. found that nicotine acutely improved 
oculomotor performance (anti-saccade latencies) in both healthy non-smokers and 
otherwise healthy smokers. Moreover, parallel to Ritsner er al.„s (Ritsner et al., 2011) 
findings of L-theanine benefits for patients suffering from schizophrenia or 
schizoaffective disorder Kumari et al. (Kumari et al. 2005) argue that nicotine entails 
cognitive benefits for patients affected with schizophrenia. In an effort to gauge the 
different self-medication hypotheses explaining the wide-spread tobacco use among 
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schizophrenics, Kumari et al.  - among other mechanisms - discuss the nicotine effect of 
increased PPI to startle response on auditory stimuli. Thus, nicotine appears to act in a 
similar way as L-theanine in the trial of Ota et al. (Ota et al., 2014). A review 
researching the supplementation of the amino-acid tyrosine (Jongkees et al., 2015) - the 
precursor to dopamine and norepinephrine - in both healthy volunteers and clinical 
groups concluded, that tyrosine administration could indeed improve cognitive function 
in both groups. However, the proposed mode of action mainly seems to come to fruition 
by furnishing the „fuel“ once neurotransmitter supply is depleted (e.g. during multi-
tasking or during demanding single-tasks). This proposed principle of action is 
fundamentally different from the postulated green tea effects, even though the cognitive 
benefits of tyrosine administration or green tea supplementation could in instances 
appear similar. Another psychoactive substance worth comparing to green tea is 
methylphenidate - e.g. through the study on healthy volunteers, with two cognitive tasks 
(motor response inhibition) and fMRI results of Costa et al (Costa et al, 2013). Similar 
to green tea, methylphenidate impacted mood, cognition and produced discernible fMRI 
peaks. There are however important differences: the changes on mood were broader 
(every dimension of VAS was increased except for „tired“), the reported cognitive 
benefits were in the domain of motority and the observed fMRI-activation resulted in 
the putamen. D-amphetamine is another known psychoactive substance to affect both 
mood and cognitive function - as illustrated in a trial on healthy subjects investigating 
oculomotor performance and impact on mood (Allman et al., 2010). Allman et al. found 
that D-amphetamine reduced anti-saccade errors, had a significant yet difficult to 
interpret influence on anti-saccade latency and significantly impacted mood in POMS 
(five out of six dimensions) and most notably led to elation. 
 
This systematic review has several limitations. Firstly, no quantitative meta-analysis 
could be performed due to the heterogeneity of the retrieved data. One aspect of the 
mentioned heterogeneity is the presence of both healthy volunteers and different kinds 
of patients in the body of the reviewed data. Even tough the studies included might 
cover a broad range of subjects, from patients to non-patients, the results show that 
green tea administration can lead to beneficial changes also in a pathological 
population. Moreover, we were very careful in the manuscript to use caution from 
generalizing the reported results of clinical studies.  
Secondly, the necessary simplifying assumption that green tea effects are the effects of 
two components that can be found almost exclusively in green tea does not account for 
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the possible effects or interactions of other components of Camellia sinensis. Also, the 
precise dose threshold for both EGCG and L-theanine for reliable acute effects on either 
cognition or mood could not be established neither in the reviewed body of work nor in 
the general scientific literature. The observed approach to determine a relevant 
intervention was either to broadly scatter the dosages of the compound in question  (Ota 
et al., 2014; L-theanine 200 mg, 400 mg and 600 mg) or - in all other cases - start from 
dosages that would typically be found in one unit of consumption (e.g. one cup of green 
tea) and then increase the studied substance up to tenfold. Similarly, the minimal period 
of time over which the long-term effective 100 ml of green tea should be consumed so 
as to confidently expect cognitive and neuropsychological benefits could not be 
determined.  
Thirdly, although data was extracted following PICOS (patient-intervention-control-
outcome-study design) and main study characteristics, no validated tool for data 
extraction was used and there was only one reviewer. 
Another difficulty arose in the lack of an evidence-based quality assessment tool for 
cross-sectional studies. What is more important, even though DELPHI and Newcastle-
Ottawa-Scale assess the most common biases, the problem of publication bias remains 
unaccounted for.  
 
Conclusion 
While this systematic review found a reasonable amount of evidence that both EGCG 
and L-theanine exhibit neuroprotective activity and that L-theanine (and to a lesser 
degree of EGCG) influence mood, the extracted data suggests that the various 
improvements in cognitive faculties linked to green tea consumption are not the 
consequence of a single component. The improvements in cognitive tasks in the 
reviewed studies are strongly linked to the presence of both caffeine and L-theanine. 
Further research is needed to establish the minimal dosage of green tea or green tea 
components to reliably elicit either acute or chronic effects, as well as what minimal 
period of time will result in long-term green tea effects. Another question for further 
research to investigate is the interaction of the two compounds and to establish whether 
EGCG too would further enhance cognitive performance in combination with caffeine.  
Also, more research is needed to corroborate the claim of EGCG effects on mood.  
Given the success of L-theanine supplementation of antipsychotic treatment for 
schizophrenia or schizoaffective disorder, further research is needed to identify other 
psychiatric treatments that could benefit from the anxiolytic properties and reduction in 
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positive symptoms from L-theanine. The extracted data suggests that it would be 
desirable for more Westerners to change their lifestyle to include habitual, daily 
consumption of green tea of at least 100 ml per day, in order to protect their 
neurocognitive function. 
 
 
Acknowledgments 
We‟d like to thank Doris Blaser for her assistance in editing this review. 
 
Conflict of interest 
There is no conflict of interest. There was no funding involved in the development of 
this review. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
25 
References 
 
Adachi, N., Tomonaga, S., Tachibana, T., Denbow, D.M., Furuse, M., 2006. (-)-
Epigallocatechin gallate attenuates acute stress responses through 
GABAergic system in the brain. European journal of pharmacology 531, 
171-175. 
Borgwardt, S., Hammann, F., Scheffler, K., Kreuter, M., Drewe, J., Beglinger, 
C., 2012. Neural effects of green tea extract on dorsolateral prefrontal 
cortex. European journal of clinical nutrition 66, 1187-1192. 
Bourassa P, Côté R, Hutchandani S, Samson G, Tajmir-Riahi HA., 2013. The 
effect of milk alpha-casein on the antioxidant activity of tea polyphenols. 
Journal of Photochemistry and Photobiology B: Biology. 128:43-49.  
Brown, A.L., Lane, J., Coverly, J., Stocks, J., Jackson, S., Stephen, A., Bluck, 
L., Coward, A., Hendrickx, H., 2009. Effects of dietary supplementation 
with the green tea polyphenol epigallocatechin-3-gallate on insulin 
resistance and associated metabolic risk factors: randomized controlled 
trial. The British journal of nutrition 101, 886-894. 
Bryan, J., 2008. Psychological effects of dietary components of tea: caffeine 
and L-theanine. Nutrition reviews 66, 82-90. 
Camfield, D.A., Stough, C., Farrimond, J., Scholey, A.B., 2014. Acute effects of 
tea constituents L-theanine, caffeine, and epigallocatechin gallate on 
cognitive function and mood: a systematic review and meta-analysis. 
Nutrition reviews 72, 507-522. 
Chen, J.J., Ye, Z.Q., Koo, M.W., 2004. Growth inhibition and cell cycle arrest 
effects of epigallocatechin gallate in the NBT-II bladder tumour cell line. 
BJU international 93, 1082-1086. 
Chow, H.H., Hakim, I.A., 2011. Pharmacokinetic and chemoprevention studies 
on tea in humans. Pharmacological research 64, 105-112. 
Davinelli, S., Sapere, N., Zella, D., Bracale, R., Intrieri, M., Scapagnini, G., 
2012. Pleiotropic protective effects of phytochemicals in Alzheimer's 
disease. Oxidative medicine and cellular longevity 2012, 386527. 
De la Torre, R., De Sola, S., Pons, M., Duchon, A., de Lagran, M.M., Farre, M., 
Fito, M., Benejam, B., Langohr, K., Rodriguez, J., Pujadas, M., Bizot, 
J.C., Cuenca, A., Janel, N., Catuara, S., Covas, M.I., Blehaut, H., 
Herault, Y., Delabar, J.M., Dierssen, M., 2014. Epigallocatechin-3-
gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome 
mouse models and in humans. Molecular nutrition & food research 58, 
278-288. 
de Morton, N.A., 2009. The PEDro scale is a valid measure of the 
methodological quality of clinical trials: a demographic study. The 
Australian journal of physiotherapy 55, 129-133. 
Del Rio, D., Calani, L., Cordero, C., Salvatore, S., Pellegrini, N., Brighenti, F., 
2010. Bioavailability and catabolism of green tea flavan-3-ols in humans. 
Nutrition 26, 1110-1116. 
Einöther, S.J., Martens, V.E., Rycroft, J.A., De Bruin, E.A., 2010. L-theanine 
and caffeine improve task switching but not intersensory attention or 
subjective alertness. Appetite 54, 406-409. 
Faria, A., Pestana, D., Teixeira, D., Couraud, P.O., Romero, I., Weksler, B., de 
Freitas, V., Mateus, N., Calhau, C., 2011. Insights into the putative 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
  
26 
catechin and epicatechin transport across blood-brain barrier. Food & 
function 2, 39-44. 
Feng, L., Gwee, X., Kua, E.H., Ng, T.P., 2010. Cognitive function and tea 
consumption in community dwelling older Chinese in Singapore. The 
journal of nutrition, health & aging 14, 433-438. 
Giesbrecht, T., Rycroft, J.A., Rowson, M.J., De Bruin, E.A., 2010. The 
combination of L-theanine and caffeine improves cognitive performance 
and increases subjective alertness. Nutritional neuroscience 13, 283-
290. 
Gomez-Ramirez, M., Higgins, B.A., Rycroft, J.A., Owen, G.N., Mahoney, J., 
Shpaner, M., Foxe, J.J., 2007. The deployment of intersensory selective 
attention: a high-density electrical mapping study of the effects of 
theanine. Clinical neuropharmacology 30, 25-38. 
Guo, S., Yan, J., Yang, T., Yang, X., Bezard, E., Zhao, B., 2007. Protective 
effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's 
disease through inhibition of ROS-NO pathway. Biological psychiatry 62, 
1353-1362. 
Haskell, C.F., Kennedy, D.O., Milne, A.L., Wesnes, K.A., Scholey, A.B., 2008. 
The effects of L-theanine, caffeine and their combination on cognition 
and mood. Biological psychology 77, 113-122. 
Higdon, J.V., Frei, B., 2003. Tea catechins and polyphenols: health effects, 
metabolism, and antioxidant functions. Critical reviews in food science 
and nutrition 43, 89-143. 
Hozawa, A., Kuriyama, S., Nakaya, N., Ohmori-Matsuda, K., Kakizaki, M., 
Sone, T., Nagai, M., Sugawara, Y., Nitta, A., Tomata, Y., Niu, K., Tsuji, I., 
2009. Green tea consumption is associated with lower psychological 
distress in a general population: the Ohsaki Cohort 2006 Study. The 
American journal of clinical nutrition 90, 1390-1396. 
Kakuda, T., 2011. Neuroprotective effects of theanine and its preventive effects 
on cognitive dysfunction. Pharmacological research 64, 162-168. 
Keenan EK, Finnie MD a, Jones PS, Rogers PJ, Priestley CM, 2011. How much 
theanine in a cup of tea? Effects of tea type and method of preparation. 
Food Chemistry;125(2):588-594.  
Kelly, S.P., Gomez-Ramirez, M., Montesi, J.L., Foxe, J.J., 2008. L-theanine and 
caffeine in combination affect human cognition as evidenced by 
oscillatory alpha-band activity and attention task performance. The 
Journal of nutrition 138, 1572S-1577S. 
Kimura, K., Ozeki, M., Juneja, L.R., Ohira, H., 2007. L-Theanine reduces 
psychological and physiological stress responses. Biological psychology 
74, 39-45. 
Kuriyama, S., Hozawa, A., Ohmori, K., Shimazu, T., Matsui, T., Ebihara, S., 
Awata, S., Nagatomi, R., Arai, H., Tsuji, I., 2006. Green tea consumption 
and cognitive function: a cross-sectional study from the Tsurugaya 
Project 1. The American journal of clinical nutrition 83, 355-361. 
Levites, Y., Amit, T., Mandel, S., Youdim, M.B., 2003. Neuroprotection and 
neurorescue against Abeta toxicity and PKC-dependent release of 
nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-
epigallocatechin-3-gallate. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology 17, 952-954. 
Levites, Y., Amit, T., Youdim, M.B., Mandel, S., 2002. Involvement of protein 
kinase C activation and cell survival/ cell cycle genes in green tea 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
27 
polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. The 
Journal of biological chemistry 277, 30574-30580. 
Lin, L.C., Wang, M.N., Tseng, T.Y., Sung, J.S., Tsai, T.H., 2007. 
Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely 
moving rats and its brain regional distribution. Journal of agricultural and 
food chemistry 55, 1517-1524. 
Mandel, S.A., Amit, T., Weinreb, O., Youdim, M.B., 2011. Understanding the 
broad-spectrum neuroprotective action profile of green tea polyphenols in 
aging and neurodegenerative diseases. Journal of Alzheimer's disease : 
JAD 25, 187-208. 
Nagle, D.G., Ferreira, D., Zhou, Y.D., 2006. Epigallocatechin-3-gallate (EGCG): 
chemical and biomedical perspectives. Phytochemistry 67, 1849-1855. 
Nance, C.L., Shearer, W.T., 2003. Is green tea good for HIV-1 infection? The 
Journal of allergy and clinical immunology 112, 851-853. 
Nobre, A.C., Rao, A., Owen, G.N., 2008. L-theanine, a natural constituent in 
tea, and its effect on mental state. Asia Pacific journal of clinical nutrition 
17 Suppl 1, 167-168. 
Ota, M., Wakabayashi, C., Matsuo, J., Kinoshita, Y., Hori, H., Hattori, K., 
Sasayama, D., Teraishi, T., Obu, S., Ozawa, H., Kunugi, H., 2014. Effect 
of L-theanine on sensorimotor gating in healthy human subjects. 
Psychiatry and clinical neurosciences 68, 337-343. 
Owen, G.N., Parnell, H., De Bruin, E.A., Rycroft, J.A., 2008. The combined 
effects of L-theanine and caffeine on cognitive performance and mood. 
Nutritional neuroscience 11, 193-198. 
Park, S.K., Jung, I.C., Lee, W.K., Lee, Y.S., Park, H.K., Go, H.J., Kim, K., Lim, 
N.K., Hong, J.T., Ly, S.Y., Rho, S.S., 2011. A combination of green tea 
extract and l-theanine improves memory and attention in subjects with 
mild cognitive impairment: a double-blind placebo-controlled study. 
Journal of medicinal food 14, 334-343. 
Pastore, R.L., Fratellone, P., 2006. Potential health benefits of green tea 
(Camellia sinensis): a narrative review. Explore 2, 531-539. 
PubMed, available at: http://www.ncbi.nlm.nih.gov/pubmed. 
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, 
J., Townsend, K., Zeng, J., Morgan, D., Hardy, J., Town, T., Tan, J., 
2005. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid 
precursor protein cleavage and reduces cerebral amyloidosis in 
Alzheimer transgenic mice. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 25, 8807-8814. 
Ritsner, M.S., Miodownik, C., Ratner, Y., Shleifer, T., Mar, M., Pintov, L., 
Lerner, V., 2011. L-theanine relieves positive, activation, and anxiety 
symptoms in patients with schizophrenia and schizoaffective disorder: an 
8-week, randomized, double-blind, placebo-controlled, 2-center study. 
The Journal of clinical psychiatry 72, 34-42. 
Scapagnini, G., Vasto, S., Abraham, N.G., Caruso, C., Zella, D., Fabio, G., 
2011. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional 
neuroprotective strategy for cognitive and neurodegenerative disorders. 
Molecular neurobiology 44, 192-201. 
Scheid, L., Ellinger, S., Alteheld, B., Herholz, H., Ellinger, J., Henn, T., Helfrich, 
H.P., Stehle, P., 2012. Kinetics of L-theanine uptake and metabolism in 
healthy participants are comparable after ingestion of L-theanine via 
capsules and green tea. The Journal of nutrition 142, 2091-2096. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
  
28 
Schmidt, A., Hammann, F., Wolnerhanssen, B., Meyer-Gerspach, A.C., Drewe, 
J., Beglinger, C., Borgwardt, S., 2014. Green tea extract enhances 
parieto-frontal connectivity during working memory processing. 
Psychopharmacology 231, 3879-3888. 
Scholey, A., Downey, L.A., Ciorciari, J., Pipingas, A., Nolidin, K., Finn, M., 
Wines, M., Catchlove, S., Terrens, A., Barlow, E., Gordon, L., Stough, C., 
2012. Acute neurocognitive effects of epigallocatechin gallate (EGCG). 
Appetite 58, 767-770. 
Shimbo, M., Nakamura, K., Jing Shi, H., Kizuki, M., Seino, K., Inose, T., 
Takano, T., 2005. Green tea consumption in everyday life and mental 
health. Public health nutrition 8, 1300-1306. 
Suganuma, M., Okabe, S., Oniyama, M., Tada, Y., Ito, H., Fujiki, H., 1998. Wide 
distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea 
polyphenol, in mouse tissue. Carcinogenesis 19, 1771-1776. 
Tomata, Y., Kakizaki, M., Nakaya, N., Tsuboya, T., Sone, T., Kuriyama, S., 
Hozawa, A., Tsuji, I., 2012. Green tea consumption and the risk of 
incident functional disability in elderly Japanese: the Ohsaki Cohort 2006 
Study. The American journal of clinical nutrition 95, 732-739. 
Türközü D, Şanlier N., 2015. L-Theanin, Unique Aminoacid of Tea, and Its 
Metabolism, Health Effects, Safety. Critical Reviews in Food Science 
and Nutrition; 8398 (March) 
Verhagen, A.P., de Vet, H.C., de Bie, R.A., Kessels, A.G., Boers, M., Bouter, 
L.M., Knipschild, P.G., 1998. The Delphi list: a criteria list for quality 
assessment of randomized clinical trials for conducting systematic 
reviews developed by Delphi consensus. Journal of clinical epidemiology 
51, 1235-1241. 
Wightman, E.L., Haskell, C.F., Forster, J.S., Veasey, R.C., Kennedy, D.O., 
2012. Epigallocatechin gallate, cerebral blood flow parameters, cognitive 
performance and mood in healthy humans: a double-blind, placebo-
controlled, crossover investigation. Human psychopharmacology 27, 
177-186. 
Yoto, A., Motoki, M., Murao, S., Yokogoshi, H., 2012. Effects of L-theanine or 
caffeine intake on changes in blood pressure under physical and 
psychological stresses. Journal of physiological anthropology 31, 28. 
Zini, A., Del Rio, D., Stewart, A.J., Mandrioli, J., Merelli, E., Sola, P., Nichelli, P., 
Serafini, M., Brighenti, F., Edwards, C.A., Crozier, A., 2006. Do flavan-3-
ols from green tea reach the human brain? Nutritional neuroscience 9, 
57-61. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
29 
Table 1 Screening criteria: Randomized, placebo-controlled studies 
 
A) Healthy volunteers, acute green tea effects 
 Participants  Intervention Study Design Outcome Measures 
Schmidt et al.
 42 12 (12 men, mean 
age: 24.1 years) 
Green tea extract (13.75 g or 27.5 g):1 g 
corresponding to 5.5 g green tea leaves; calculated 
contents: EGCG (4700 mg or 9400 mg), L-theanine 
(400 mg or 800 mg), caffeine (1350 mg or 2700 
mg) 
Double-blind, controlled, 
counterbalanced within- 
subject trial 
Working memory n-back task, fMRI 
Borgwardt et al.
 2 12 (12 men, mean 
age: 24.1 years) 
Green tea extract (13.75 g or 27.5 g):1 g 
corresponding to 5.5 g green tea leaves; calculated 
contents: EGCG (4700 mg or 9400 mg), L-theanine 
(400 mg or 800 mg), caffeine (1350 mg or 2700 
mg) 
Double-blind, controlled, 
counterbalanced within-
subject trial 
Working memory n-back task, fMRI  
Scholey et al.
 43 31 (12 men, mean 
age: 27.7 years) 
Green tea extract (caffeine free) of which 94% 
EGCG (300 mg) and 6% vitamin C 
Double-blind, controlled 
crossover trial 
EEG, VAS 
Wightman et al.
 48 27 (11 men, mean 
age: 22 years) 
EGCG (135 mg or 270 mg) 
Double-blind, controlled, 
balanced crossover trial 
Near infrared spectroscopy, odd-ball reaction time, 
simple reaction time, serial subtractions, RVIP, Stroop 
task, VAS 
Ota et al.
 34 14 (7 men, mean 
age: 31.0 years) 
L-theanine (200 mg, 400 mg, 600 mg) 
Double-blind, controlled, 
counterbalanced cross-over 
trial 
Prepulse inhibition test 
Yoto et al.
 49 16 (8 men, mean 
age: 22.8 years) 
L-theanine (200 mg) or caffeine  
Randomised, controlled, 
crossover trial 
Stress-load task, physiological measurement, 
POMS, VAS 
Giesbrecht et al.
 16 44 (16 men, mean 
age: 21.2 years) 
L-theanine (97 mg) and caffeine (40 mg) 
Double-blind, randomised, 
controlled, counterbalanced 
within-subject trial 
Physiological measurement, choice-reaction-time task, 
visual-search task, egocentric mental-rotation task, 
attention-switching-task, task demand rating scale, 
VAS 
Ein ther et al.
 13 29 (11 men, mean 
age: 30.6 years) 
L-theanine (97 mg) and caffeine (40 mg) 
Double-blind, randomised, 
controlled, crossover trial 
Intersensory attention task, switch task, VAS 
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 Participants  Intervention Study Design Outcome Measures 
Owen et al.
 35 27 (14 men, mean 
age: 28.3 years) 
L-theanine (100 mg) and caffeine (50 mg) 
Double-blind, randomised, 
controlled, crossover trial 
Word recognition, RVIP, CFFT, Attention-switching 
task, VAS 
Kelly et al.
 24
 
16 (11 men, mean 
age: 27.5 years) 
L-theanine (100 mg) or L-theanine (100 mg) and 
caffeine (50 mg) 
controlled, balanced, 
repeated-measures trial 
EEG, neurocognitive test 
Haskell et al.
 19
 
24 (9 men, mean 
age: 21.3 years) 
 
L-theanine (250 mg) or L-theanine (250 mg) and 
caffeine (150 mg) 
Double-blind, randomised, 
controlled, balanced 
crossover trial 
CDR: simple reaction time, digit vigilance reaction 
time, RVIP, spatial memory accuracy, numeric 
working memory reaction time, delayed word 
recognition reaction time, sentence verification 
accuracy, serial sevens subtraction task, VAS, 
CRVAS 
Kimura et al.
 25
 
12 (12 men, mean 
age: 21.5 years) 
L-theanine (200 mg) 
Double-blind, controlled, 
counterbalanced crossover 
trial 
Physiological measurement, VAS, state-trait anxiety 
inventory  
CFFT: critical flicker fusion threshold; EEG: electroencephalography; EGCG: epigallocatechin gallate; fMRI: functional magnetic resonance imaging; POMS: profile of mood 
states; RVIP: rapid visual information processing; VAS: visual analogue scale 
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B) Patients, non-acute green tea effects 
 Participants Intervention Study Design Outcome Measures 
De la Torre et al.
 9 
29 (15 male, 
patients with Down 
Syndrome, mean 
age: 21.3 years)  
EGCG (360 mg)* 
caffeine (25 mg) 
*9 mg/kg/d 
Double-blind randomised, 
controlled pilot study (12 
weeks) 
CANTAB: psychomotor speed, attention, episodic 
memory, executive functions, visuomotor precision. 
Parents/caregivers: scales of functional ability in daily 
living, adaptive behaviour, QLS 
Park et al. 
36 
91 (25 men 40-75 
years) mild 
cognitive 
impairment 
(MMSE-K 21-26) 
Green tea extract (360 mg) and L-theanine (60 
mg), twice a day 
Double-blind, controlled trial 
(16 weeks) 
MMSE-K, GDS, Rey-Kim memory test, Stroop color-
word reading test, EEG 
Ritsner et al.
 39 
60 (48 men, mean: 
36.5 years) 
schizophrenia or 
schizo-affective 
disorder 
L-theanine (400 mg) and antipsychotic medication 
Double-blind, randomized, 
controlled (2-Centre) trial (8 
weeks) 
CGI-S, PANSS, CDSS, HARS, CANTAB, GAF, ESRS, 
QLS, Q-LES-Q-18 
CANTAB: Cambridge neuropsychological test automated battery; CDSS: Calgary depression scale for schizophrenia; CGI-S: clinical global impressions-severity of illness scale; 
EGCG: epigallocatechin gallate EEG: electroencephalography; ESRS: extrapyramidal symptom rating scale GAF: global assessment of functioning GDS: global deterioration 
scale; HARS: Hamilton anxiety rating scale; MMSE-K: mini mental scale examination-Korean; PANSS: positive and negative syndrome scale Q-LES-Q-18: quality of life 
enjoyment and satisfaction questionnaire- abbreviated version, QLS: guality of life scale 
Brown et al.
 3 
100 (100 men, age 
40-65 years) 
Obesity with BMI 
> 28 and < 38 
kg/m2 
EGCG (800 mg) 
Double-blind, randomized, 
parallel design (matched for 
insulin resistance and age) 
trial (8 weeks) 
UWIST mood adjective checklist, physiological 
measurements 
EGCG: epigallocatechin gallate; UWIST: university of Wales of Science and Technology 
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C) Observational studies: Long-term green tea effects 
 Participants Exposure Time/Duration Study Design Outcome Measures 
Tomata et al.
 46 
23,091( ≥ 65 years) 
Green tea consumption (and other tea 
and coffee) 
2006 
3 year follow-up 
Prospective cohort study survey, long-term care insurance certification 
Feng et al.
 15 716 ( ≥ 55 years mean: 
64.5 years) 
Green tea consumption 
(and general tea consumption) 
? 
cross sectional study set 
in the Singapore 
Longitudinal Ageing 
Studies 
Questionnaire, interview, MMSE, attention-, 
memory-, executive function-, information 
processing speed-score 
Hozawa et al.
 22 
42,093 ( ≥ 40 years) 
Green tea consumption (and other tea 
and coffee) 
2006 
cross-sectional study set 
in Ohsaki Cohort 2006 
study 
Kessler 6-item psychological distress scale 
Kuriyama et al.
 26 
1,003 ( ≥  70 years) 
Green tea consumption 
(and other tea and coffee consumption) 
2002 
cross sectional study of 
Comprehensive Geriatric 
Assessment (2002) 
Questionnaire (comprehensive geriatric 
assessment), MMSE 
Shimbo et al.
 44 387 (20-69 years mean 
46 years) 
Green tea consumption  (and other tea, 
coffee and caffeine-containing 
beverages consumption) 
2002 cross-sectional study General health questionnaire, interview 
MMSE: mini mental state examination 
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Table 2 Cardiovascular, neuropsychological and imaging results of the reviewed studies. 
Experimental studies 
Healthy volunteers, acute green tea effects 
 cardiovascular effects neuropsychological effects neurocognitive effects brain functions 
Schmidt et al.
 42 
not tested not tested 
not significant; the magnitude of green 
tea induced increase in parieto-frontal 
connectivity positively correlated with 
improvement in task performance (p = 
0.066) 
increased the working memory 
induced modulation of connectivity 
from the right superior parietal 
lobule to the middle frontal gyrus.  
Borgwardt et al.
 2 
not tested not tested no data 
increased activation in dorsolateral 
prefrontal cortex bilaterally (p < 
0.001*) (fMRI) 
*family wise-error adjusted 
Scholey et al.
 43 
not tested 
increased calmness (p = 0.04) and 
reduced stress (p = 0.017) (VAS) 
not tested 
increased overall alpha, beta and theta 
activity (LORETA: frontal gyrus and 
medial frontal gyrus, Brodmann area 6 
and 10) (p = 0.001) in EEG (eyes 
open) 
Wightman et al.
 48 
not significant not significant not significant 
135 mg EGCG reduced cerebral blood 
flow in the frontal cortex (p < 0.05) 
(NIRS, oxygenated haemoglobin) 
Ota et al.
 34 
not tested not tested not tested 
increases sensorimotor gating 
(percentage of prepulse inhibition) in 
dose range (200 mg and 400 mg, but 
not 600 mg) dosage independently 
(p < 0.05) 
Yoto et al.
 49 
reduced systolic blood pressure 
increment (p = 0.008) 
 in high stress-responders 
reduced tension-anxiety scores (p = 
0.004) (POMS) 
not significant not tested 
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 cardiovascular effects neuropsychological effects neurocognitive effects brain functions 
Giesbrecht et al.
 16 
combination: 
increased systolic blood pressure (p = 
< 0.01) 
combination: 
increased self-reported alertness (p < 
0.01) (VAS), 
reduced self-reported tiredness (p < 
0.05) (task demand rating scale) 
combination: 
improved accuracy in attention-
switching task (p < 0.01) 
not tested 
EGCG: epigallocatechin gallate; EEG: electroencephalography; fMRI: functional magnetic resonance imaging;  LORETA: low resolution brain electromagnetic tomography; 
NIRS: near infrared spectroscopy VAS: visual analogue scale 
Ein ther et al.
 13 
not tested not significant 
combination: 
improved accuracy in switch task (p = 
0.003) 
not tested 
Owen et al.
 35 
not tested not significant 
combination: 
improved speed and accuracy in 
attention-switching task (p < 0.001), 
reduced susceptibility to distraction (p 
< 0.01)(word recognition) 
not tested 
Kelly et al.
 24 
not tested not tested 
combination: 
improved accuracy (p < 0.002) and hit 
rate (p < 0.016) in especially devised 
cognitive test 
combination: 
lowered overall tonic alpha amplitude 
(p < 0.02) (EEG) 
Haskell et al.
 19 
not tested 
L-theanine:  
increased headache* (p < 0.05) 
combination: 
increased self-reported alertness(p < 
0.01) (VAS), decreased self-reported 
tiredness*(p < 0.005), mental fatigue* 
(p < 0.05) and headache* (p < 0.05) 
(all VAS / CRVAS) 
*data capture error: only 23 
participants 
L-theanine: 
deteriorated serial sevens** (p < 0.05) 
combination: 
improved simple reaction time (p < 
0.05), accuracy of RVIP (p < 0.001), 
numeric working memory reaction 
time (p < 0.05),  
delayed word recognition time (p < 
0.05) and accuracy of sentence 
verification** (p < 0.05) 
** data capture error: only 22 
participants 
not tested 
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 cardiovascular effects neuropsychological effects neurocognitive effects brain functions 
Kimura et al.
 25 reduced heart rate increment (p < 0.05) 
and s-IgA increment  (p < 0.01) 
reduced self-reported stress (p < 0.01) 
and self-reported anxiety (p < 
0.01)(VAS and STAI) 
 
not tested not tested 
CRVAS: caffeine research visual analogue scale; EEG: electroencephalography; VAS: visual analogue scale RVIP: rapid visual information processing; s-IgA: secretory 
immunoglobulin A; STAI: state-trait anxiety inventory  
 
Patients, non-acute green tea effects 
 cardiovascular effects neuropsychological effects neurocognitive effects brain functions 
De la Torre et al.
 9 
increases plasma homocysteine levels 
(p = 0.024; biomarker for DYRK1A 
activity) after 1 month of treatment. 
reduces plasma cholesterol (p = 0.02 
and LDL cholesterol (p = 0.014) after 3 
months of treatment. 
improved social functioning on the 
Kidscreen-27 quality of life index 
„social Support & Peers“  (p = 0.05) 
increases visual memory recognition 
(p = 0.04) 
not tested 
Park et al.
 36 
not significant not tested 
increased both verbal/visuospatial 
memory (p = 0.0478)(Rey Kim 
memory test) and attention  (p = 0.306, 
after 8 weeks) (Stroop colour-word 
reading test) in more affected subgroup 
(MMSE-K 21-23)  
increased theta waves during „eyes-
open“ (p < 0.005) and „reading“ states 
(p < 0.05) (EEG of 23 random 
subjects) 
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 cardiovascular effects neuropsychological effects neurocognitive effects brain functions 
 Ritsner et al.
 39 
not tested 
reduced positive (p = 0.004*) and 
activation factor (p = 0.006*) (in 5-
dimensional PANSS), positive (p = 
0.009**) and general psychopathology 
sub-scales (p < 0.001**) (in 3-
dimensional PANSS) and anxiety 
scores (p = 0.015**) (HARS) 
*Bonferroni correction for 3 tests was 
applied 
**Bonferroni correction for 5 tests was 
applied 
not significant not tested 
L. Brown et al.
 3 reduced diastolic blood pressure (p = 
0.014) 
increased hedonic tone (p = 0.048) not tested not tested 
DYRK1A: dual specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A; EEG: electroencephalography HARS: Hamilton anxiety rating scale; LDL: low-density lipoprotein; 
MMSE-K: mini mental state examination - Korean; PANSS: positive and negative syndrome scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
37 
 
Observational studies 
Long-term green tea effects 
 cardiovascular effects neuropsychological effects neurocognitive effects brain functions 
Tomata et al.
 46 
tested, yet no supplied data not tested, see Hozawa et al.
 22 
decreased OR for functional disability 
related to dosage: 1-2 cups/d OR 0.9, 
3-4 cups/d OR 0.76 and ≥ 5 cups/d OR 
0.67 in reference to < 1cups/d (p < 
0.001) 
not tested 
Feng et al.
 15 tested, yet mixed with other tea and 
coffee consumption 
tested, yet mixed with other tea and 
coffee consumption 
increased performance in MMSE (p = 
0.02), memory-score (p = 0.01), 
executive function-score (p = 0.01) and 
information processing speed-score (p 
= 0.04) 
not tested 
Hozawa et al.
 22 
associated with less history of stroke (p 
< 0.001) and more history of cancer (p 
< 0.007) 
reduced OR for physiological distress 
(Kessler 6-item physiological distress 
scale) related to dosage: 1-2 cups/d OR 
0.95, 3-4 cups/d OR 0.89, > 5 cups/d 
OR 0.80 in reference to < 1 cups/d (p < 
0.001) 
not tested, see Tomata et al.
 46 
not tested 
Kuriyama et al.
 26 
not significant not significant 
decreased the OR of cognitive 
impairment (MMSE < 26): 0.57-0.86 
cups/d OR 0.62, 2-3 cups/d OR 0.42, ≥ 
4 cups/d OR 0.49 (p < 0.004)in 
reference to ≤0.43 cups/d (p = 0.004) 
not tested 
Shimbo et al.
 44 
not tested not significant 
green tea effects not significant, 
daily caffeine (including green tea) 
intake of 100 mg increased risk for 
mental ill-health among females, 
OR1.26 (p = 0.04) 
not tested 
1 cup of tea equals 100 ml; MMSE: mini mental state examination; OR: odds ratio 
 
 
